Construction of Drug Utilization Evaluation Criteria for Oliceridine Injection Using the Attribute Hierarchy Model-technique for Order Preference by Similarity to an Ideal Solution Method and Its Application in a Multicenter Real-World Study

OBJECTIVE To establish drug utilization evaluation(DUE) standards for oliceridine injection, evaluate and analyze oliceridine's clinical application.

METHODS Based on drug package inserts, clinical practice guidelines, and expert consensus, the Delphi method was employed to establish the DUE standards for oliceridine, and the attribute hierarchy model(AHM) was used to determine the comprehensive weights of the indicators. A retrospective study was conducted, in which the rationality of 493 discharged medical records from January 1, 2025, to November 30, 2025, was evaluated using thetechnique for order preference by similarity to an ideal solution(TOPSIS).

RESULTS The established DUE standards comprised 3 primary indicators(indication, administration process, and treatment outcome) and 11 secondary indicators(indications, contraindications, special populations, etc.). The secondary indicators with the highest weight coefficients were indications(0.0833) and contraindications(0.0833). A total of 493 medical records were included. According to the results of the weighted TOPSIS evaluation, 391 cases(79.3%) were rational, and 102 cases(20.7%) were basically rational. The primary types of irrational drug use involved use in special populations(42 cases, 8.5%) and exceeding daily dose limits or treatment duration(32 cases, 6.5%).

CONCLUSION The clinical application of oliceridine is generally rational, but its usage requires further standardization. The established DUE standards for oliceridine are feasible and can serve as a reference for the management of rational clinical drug use.